A variety of procedures may be employed for hidradenitis suppurativa, a chronic cutaneous condition that causes abscesses, nodules, and tunnels in skinfold areas. Intralesional steroid or incision and drainage are preferred for acutely inflamed discrete lesions, while deroofing or excision may be pursued for persistent or recurrent areas. Excision and deroofing may target individual lesions or complete regions that are more widely affected. Reconstructions may be considered after excisions based on operator and patient preference. Other procedures such as botulinum toxin injection, cryoinsufflation, and electrosurgical and laser-based modifications to deroofing and excisions have also been used successfully.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.det.2024.12.012 | DOI Listing |
J Eur Acad Dermatol Venereol
March 2025
Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Hidradenitis suppurativa (HS) adversely affects quality of life, education, work, relationships and mental health. The debilitating effects of HS can compound over a patient's lifetime and have lasting repercussions. The cumulative life course impairment (CLCI) model analyses the disease factors that could affect the life course trajectory of a patient, including effects on major life decisions and opportunities, such as relationships, career path, education and starting a family.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
March 2025
Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany.
Background: Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase III studies.
Objective: To evaluate the relative efficacy and safety of biologics for HS in a network meta-analysis including available data from phase III trials.
Methods: MEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate-to-severe HS.
JAAD Int
April 2025
Department of Dermatology, University of Southern California, Los Angeles, California.
JAAD Int
April 2025
Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Cutan Ocul Toxicol
March 2025
Department of Dermatology, Dicle University Faculty of Medicine, Diyarbakır, Turkey.
Objective: Recently, adalimumab has become an important drug frequently used by dermatologists in the treatment of Hidradenitis suppurativa. While there are many publications by rheumatologists about the risk of hepatitis B and tuberculosis reactivation, the literature on reactivation in the treatment of hidradenitis is not extensive. With this study, we wanted to emphasize that adalimumab is a safe drug despite the risk of hepatitis B and tuberculosis reactivation and the importance of porphylaxis during the treatment of hidradenitis suppurativa.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!